# Diabetes Research Hub — Daily Iteration Report

**Date:** 2026-08-10 (Monday — weekly sweep due)
**Run:** #117

## State at run
- **Papers:** 287 (274 VETTED / 13 FLAGGED / 0 UNVETTED) — +1 this run (PMID 41548682)
- **Paths:** 57 | **Work queue:** 40 | **Prior runs:** 116

## Work done

### 1. Weekly PubMed sweep (7 topics, web-based)
| Topic | Finding | Action |
|---|---|---|
| LADA | New 2026 narrative review (Rev. Colomb. Endocrinol.) + SN Compr. Clin. Med. 2025 "Evolving Landscape" review | No practice-changing result; noted |
| Islet transplant | Eledon **tegoprubart 12/12 insulin-independent** (Jun-8-2026); Vertex Ph3, Sana hypoimmune, Sernova 8/12 | All already tracked |
| NLRP3 × DKD | Immunity Inflamm. Dis. (10.1002/iid3.70424); Front. Immunol. sEH (10.3389/fimmu.2026.1767802); IJMS 27(10):4257 ferroptosis (already PENDING/not-indexed) | Mechanistic reinforcement only; none clinical |
| Drug repurposing (generic) | Verapamil/JAKi/lesogaberan/pitavastatin+L-glutamine | Preclinical, consistent with catalog |
| Oxidative-stress combo | Astaxanthin+metformin RCT (12wk); ALA/CoQ10/NAC reproducible but not disease-modifying | No change |
| Verapamil T1D | Ver-A-T1D adult equivocal/underpowered | Already RESOLVED |
| Dapagliflozin + colchicine | No direct combo RCT | See combination note below |

### 2. Path validation — metformin → nephropathy
**REAFFIRMED PARTIALLY_VALIDATED.** The 2026 Eur. J. Pharmacol. systematic review/meta-analysis previously cited **by DOI only** (S0014299926000427) now resolves to a **real PubMed PMID: 41548682** (12 studies, search to Sep-2025):
- All-cause mortality **HR 0.76 (0.64–0.90)**
- ESRD **HR 0.61 (0.49–0.76)**
- Lactic-acidosis trend in stage-4 CKD **HR 1.93 (0.95–3.87)**
- No MACE association; **certainty VERY LOW** (observational)

Rating held at PARTIALLY_VALIDATED: renal-protective/safety signal strengthens, but **still no RCT with nephropathy/CKD as a primary endpoint** (contrast SGLT2i CKD-primary RCTs). PMID added to path `external_pmids` and to the paper library as VETTED.

### 3. Combination check — SGLT2i + colchicine
Paper **CONFIRMED REAL** (ScienceDirect S033306202500132X; ResearchGate 397172145/395261777) but **STILL NOT PubMed-indexed** — no PMID. Propensity-matched retrospective/observational: dual therapy associated with lower all-cause mortality, MACE, and HF exacerbations vs colchicine alone in CAD+T2D, benefit by 6mo persisting to 1yr, strongest in reduced-EF. **Kept PENDING** (observational, no PMID); recheck for indexing ~2026-09-10.

### 4. Credibility sweep (.py scripts) — CLEAN
Zero fabricated PMIDs; zero "zero SAEs/rejection"; the only "curative" hits are inside the `verify_before_deploy.py` checker regex itself. Doctrine already documents the "≥42M PMID = fabricated" heuristic as STALE (reconfirmed 2026-08-08) — real 2026 PMIDs legitimately reach that range; verification is by NCBI round-trip, not numeric ceiling.

### 5. Pipeline rebuild — 38/38 offline scripts [OK]
Ran in two batches (18 + 20). The 3 network scripts (`verify_pmids`, `track_unfound_pmids`, `ingest_papers`) were **skipped** — live PubMed stalls in the sandbox, per standing doctrine. All dashboards/JSON regenerated.

## Git
Commit attempted; **PUSH remains BLOCKED** (no GitHub auth in sandbox). All changes are saved to working files on disk regardless. **USER action:** `git push` from local PowerShell at `C:\Users\justi\OneDrive\Diabetes_Research`.

## Next run (queue guidance)
- SAB-142 & tegoprubart peer-reviewed-pub rechecks due ~2026-08-17
- Gap #3 / Gap #6 monthly audits due ~2026-08-16
- Next stale path to validate: calcineurin→islet_transplant or canagliflozin→inflammation
